KLOW Protocol
Four-Peptide Regenerative Blend
KLOW builds upon GLOW protocol by adding KPV for enhanced anti-inflammatory action. This combination lacks clinical trials on the specific four-peptide formulation despite individual component research. Standard vial contains 80mg blend (50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, 10mg KPV).
Mechanism of Action
Each peptide contributes distinct biological pathways: GHK-Cu modulates gene expression for tissue repair, TB-500 enhances cellular migration and wound healing, BPC-157 upregulates growth factors for tissue regeneration, and KPV inhibits NF-κB inflammatory pathway.
Key Benefits
- Theoretical synergistic multi-pathway tissue repair
- Anti-inflammatory effects across multiple mechanisms
- Cellular regeneration support
- Convenience of single injection dosing
- KPV may reduce injection site reactions versus GLOW
GHK-Cu + TB-500 + BPC-157 + KPV (5:1:1:1 ratio) Complex or non-standard sequence format
Primary Applications
- Wound Healing
Multi-modal healing addressing tissue through complementary pathways
- Post-Surgical Recovery
Enhanced tolerability with KPV versus GLOW formulation
- Sports Injury Management
Single injection convenience factor
- Skin Rejuvenation
Collagen stimulation and tissue regeneration
Subcutaneous injection with rotation between abdomen, thighs, and upper arms.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Conservative approach | 200mcg total daily | Once daily evening | Subcutaneous |
| Standard research protocol | 200-500mcg total | Once daily | Subcutaneous |
| Cycling protocol | Per standard dosing | 4-6 weeks on, 2-4 weeks off | Subcutaneous |
Reconstitution Instructions
- KLOW 80mg vial
- Bacteriostatic water (2-5mL)
- Insulin syringes
- Alcohol prep pads
- 1 Clean vial top with alcohol pad
- 2 Add 4mL bacteriostatic water (creates 20mg/mL)
- 3 Gently swirl - do not shake
- 4 Solution should appear clear to slightly cloudy
- 5 Label with date and concentration
- 6 Store refrigerated immediately
- 7 Use within 4-6 weeks
KLOW contains all GLOW components plus KPV—combining causes double-dosing
No studies on combination; theoretical compatibility based on different mechanisms
No data combining KLOW with NAD+; both affect cellular processes differently
Components may affect wound healing and clotting—medical supervision required
Multiple components affect GH pathways; risk of excessive stimulation
Components may interfere with immunosuppressive therapy
Some users report inflammation reduction within days
Wound healing effects may develop if they manifest
Full cycle effects; assess response
2-4 weeks off between cycles recommended
Common Side Effects
- Injection site reactions (common even with KPV)
- Individual responses vary widely
Stop Signs - Discontinue if:
- Severe injection site reactions or infection
- Allergic reactions (rash, difficulty breathing)
- Unusual fatigue or weakness
- Signs of copper toxicity (nausea, jaundice)
- Worsening of underlying conditions
Contraindications
- No safety studies on four-peptide combination
- Long-term effects completely unknown
- FDA has not approved any component for therapeutic use
Good Signs
- Third-party testing (Janoshik or similar)
- Reputable research supplier with quality control
- Certificate of Analysis provided
Warning Signs
- Research-only status - not approved for human use
- Batch variability - ratios and purity may vary
Bad Signs
- Vendors without Certificate of Analysis
- Suspiciously low prices suggest counterfeits
- Individual Component Research—GHK-CuMultiple Studies (Various)
GHK-Cu demonstrates wound healing, anti-aging, and gene modulation effects in isolation
- BPC-157 Limited Human DataHuman pilot study (2020)
Small pilot showed 10 of 12 patients achieved complete symptom resolution in interstitial cystitis
- No Published Studies on KLOW CombinationN/A (2024)
Scientific studies examining safety or efficacy of the four-peptide KLOW combination do not exist
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.